J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maïga et al., A highrisk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

S. Manier, K. Z. Salem, J. Park, D. A. Landau, G. Getz et al., Genomic complexity of multiple myeloma and its clinical implications, Nat Rev Clin Oncol, vol.14, issue.2, pp.100-113, 2017.
DOI : 10.1038/nrclinonc.2016.122

P. Sonneveld, H. Avet-loiseau, S. Lonial, S. Usmani, D. Siegel et al., Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood, vol.127, issue.24, pp.2955-62, 2016.

P. Moreau, M. Cavo, P. Sonneveld, L. Rosinol, M. Attal et al., Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death, J Clin Oncol, vol.32, issue.20, pp.2173-80, 2014.

P. Sonneveld, D. Wit, E. Moreau, and P. , How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?, Crit Rev Oncol Hematol, vol.112, pp.153-70, 2017.

B. Tessoulin, G. Descamps, P. Moreau, S. Maïga, L. Lodé et al., PRIMA1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, issue.10, pp.1626-1662, 2014.

S. Maïga, C. Brosseau, G. Descamps, C. Dousset, P. Gomez-bougie et al., A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, issue.4, pp.285-293, 2015.

F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.

S. Surget, D. Chiron, P. Gomez-bougie, G. Descamps, E. Ménoret et al., Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.72, issue.17, pp.4562-73, 2012.

L. Bodet, P. Gomez-bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3911, 2011.

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.28, issue.1, pp.210-212, 2014.

S. Surget, E. Lemieux-blanchard, S. Maïga, G. Descamps, L. Gouill et al., Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other, Leuk Lymphoma, vol.55, issue.9, pp.2165-73, 2014.

S. Surget, G. Descamps, C. Brosseau, V. Normant, S. Maïga et al., RITA (reactivating p53 and inducing tumor apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway, BMC Cancer, vol.14, p.437, 2014.

C. Kervoëlen, E. Ménoret, P. Gomez-bougie, R. Bataille, C. Godon et al., Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma, Oncotarget, vol.6, issue.29, pp.26922-26956, 2015.

M. Gerstung, A. Pellagatti, L. Malcovati, A. Giagounidis, M. Porta et al., Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes, Nat Commun, vol.6, p.5901, 2015.

G. Yu and Q. He, ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization, Mol Biosyst, vol.12, issue.2, pp.477-486, 2016.
DOI : 10.1039/c5mb00663e

G. Yu, L. Wang, Y. Han, and Q. He, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, vol.16, issue.5, pp.284-291, 2012.
DOI : 10.1089/omi.2011.0118

URL : http://europepmc.org/articles/pmc3339379?pdf=render

A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, Maftools: efficient and comprehensive analysis of somatic variants in cancer, Genome Res, vol.28, issue.11, pp.1747-56, 2018.

X. Zheng, D. Levine, J. Shen, S. M. Gogarten, C. Laurie et al., A highperformance computing toolset for relatedness and principal component analysis of SNP data, Bioinformatics, vol.28, issue.24, pp.3326-3334, 2012.

B. A. Walker, E. M. Boyle, C. P. Wardell, A. Murison, D. B. Begum et al., Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma, J Clin Oncol, vol.33, issue.33, pp.3911-3931, 2015.

M. A. Chapman, M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez et al., Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, issue.7339, pp.467-72, 2011.
DOI : 10.1038/nature09837

URL : https://www.nature.com/articles/nature09837.pdf

J. G. Lohr, P. Stojanov, S. L. Carter, P. Cruz-gordillo, M. S. Lawrence et al., Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, issue.1, pp.91-101, 2014.

S. S. Chavan, J. He, R. Tytarenko, S. Deshpande, P. Patel et al., Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker, Blood Cancer J, vol.7, issue.2, p.535, 2017.

N. Weinhold, C. Ashby, L. Rasche, S. S. Chavan, C. Stein et al., Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma, Blood, vol.128, issue.13, pp.1735-1779, 2016.
DOI : 10.1182/blood-2016-06-723007

URL : http://www.bloodjournal.org/content/128/13/1735.full.pdf

M. Barbieri, M. Manzoni, S. Fabris, G. Ciceri, K. Todoerti et al., Compendium of FAM46C gene mutations in plasma cell dyscrasias, Br J Haematol, vol.174, issue.4, pp.642-647, 2016.

I. Cifola, M. Lionetti, E. Pinatel, K. Todoerti, E. Mangano et al., Wholeexome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Oncotarget, vol.6, pp.17543-58, 2015.
DOI : 10.18632/oncotarget.4028

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=4028&path%5B%5D=10008

M. Lionetti, M. Barbieri, K. Todoerti, L. Agnelli, S. Marzorati et al., Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, vol.6, issue.27, pp.24205-24222, 2015.

M. Lionetti, M. Barbieri, M. Manzoni, S. Fabris, C. Bandini et al., Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature, Oncotarget, vol.7, issue.16, pp.21353-61, 2016.

A. Jurczyszyn, J. J. Castillo, I. Avivi, J. Czepiel, J. Davila et al., Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, Leuk Lymphoma, vol.0, issue.0, pp.1-6, 2018.

A. Lagana, D. Melnekoff, I. Beno, V. Leshchenko, D. Perumal et al., Clonal evolution in newly diagnosed multiple myeloma patients: a followup study from the Mmrf Commpass Genomics Project, Blood, vol.130, issue.1, p.325, 2017.

N. Lehners, U. H. Toprak, J. Xu, N. Paramasivam, D. Hübschmann et al., Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance, Blood, vol.130, issue.1, p.266, 2017.

C. Pawlyn, M. F. Kaiser, C. Heuck, L. Melchor, C. P. Wardell et al., The spectrum and clinical impact of epigenetic modifier mutations in myeloma, Clin Cancer Res, vol.22, issue.23, pp.5783-94, 2016.

B. Tessoulin, M. Eveillard, A. Lok, D. Chiron, P. Moreau et al., p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell, Blood Rev, vol.31, issue.4, pp.251-59, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01493742

Z. Tao, L. Hasvold, L. Wang, X. Wang, A. M. Petros et al., Discovery of a potent and selective BCL-XL inhibitor with in vivo activity, ACS Med Chem Lett, vol.5, issue.10, pp.1088-93, 2014.

J. D. Leverson, H. Zhang, J. Chen, S. K. Tahir, D. C. Phillips et al., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death Dis, vol.6, p.1590, 2015.

R. S. Finn, J. Dering, D. Conklin, O. Kalous, D. J. Cohen et al., PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, vol.11, issue.5, p.77, 2009.

C. M. Annunziata, R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea et al., Frequent engagement of the classical and alternative NF-?B pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007.

W. Nieves-neira, M. I. Rivera, G. Kohlhagen, M. L. Hursey, P. Pourquier et al., DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells, Mol Pharmacol, vol.56, issue.3, pp.478-84, 1999.

H. C. Lee, H. Wang, V. Baladandayuthapani, H. Lin, J. He et al., RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma, Br J Haematol, vol.177, issue.1, pp.80-94, 2017.

N. Bolli, Y. Li, V. Sathiaseelan, K. Raine, D. Jones et al., A DNA targetenrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma, Blood Cancer J, vol.6, issue.9, p.467, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01382540

H. G. Drexler, W. G. Dirks, and R. A. Macleod, False human hematopoietic cell lines: cross-contaminations and misinterpretations, Leukemia, vol.13, issue.10, pp.1601-1608, 1999.
DOI : 10.1038/sj.leu.2401510

URL : http://www.nature.com/articles/2401510.pdf

H. G. Drexler, W. G. Dirks, R. A. Macleod, and C. C. Uphoff, False and mycoplasmacontaminated leukemia-lymphoma cell lines: time for a reappraisal, Int J Cancer, vol.140, issue.5, pp.1209-214, 2017.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

M. E. Klein, M. Kovatcheva, L. E. Davis, W. D. Tap, and A. Koff, CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought, Cancer Cell, vol.34, issue.1, pp.9-20, 2018.

R. Niesvizky, A. Z. Badros, L. J. Costa, S. A. Ely, S. B. Singhal et al., Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma, Leuk Lymphoma, vol.56, issue.12, pp.3320-3328, 2015.

J. P. Leonard, A. S. Lacasce, M. R. Smith, A. Noy, L. R. Chirieac et al., Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma, Blood, vol.119, issue.20, pp.4597-607, 2012.

D. Kwapisz, Cyclin-dependent kinase 4/6 inhibitors in hormone receptorpositive early breast cancer: preliminary results and ongoing studies, Breast Cancer, vol.25, issue.5, pp.506-522, 2018.

A. Lok, G. Descamps, B. Tessoulin, D. Chiron, M. Eveillard et al., Pellat-Deceunynck C. p53 regulates CD46 expression and Measles virus infection in myeloma cells. Blood Advances

S. Mroczek, J. Chlebowska, T. M. Kuli?ski, O. Gewartowska, J. Gruchota et al., The non-canonical poly(A) polymerase FAM46C acts as an oncosuppressor in multiple myeloma, Nat Commun, vol.8, issue.1, p.619, 2017.

J. W. Schoggins, S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones et al., A diverse range of gene products are effectors of the type I interferon antiviral response, Nature, vol.472, issue.7344, pp.481-486, 2011.

A. Dispenzieri, C. Tong, B. Laplant, M. Q. Lacy, K. Laumann et al., Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma, Leukemia, vol.31, issue.12, pp.2791-2799, 2017.

A. Christofferson, S. Nasser, J. Aldrich, D. Penaherrera, C. Legendre et al., Integrative analysis of the genomic landscape underlying multiple myeloma at diagnosis: an Mmrf Commpass Analysis, Blood, vol.130, issue.1, p.326, 2017.

A. Kotschy, Z. Szlavik, J. Murray, J. Davidson, A. L. Maragno et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, issue.7626, pp.477-82, 2016.